NCT04875754View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Osteoarthritis, Knee
Interventions
GENETIC

ICM-203

Intra-articular injection

DRUG

Placebo

Intra-articular injection

Trial Locations (2)

3220

Barwon Health, Geelong

5000

Royal Adelaide Hospital, Adelaide

Sponsors
All Listed Sponsors
lead

ICM Biotech Australia Pty Ltd.

INDUSTRY